MedCity News October 14, 2021
The startup shared results of a prospective study showing its deep learning software detected melanoma with 93% sensitivity and 91% specificity.
Not long after Paige cinched FDA clearance for its algorithm to flag potentially cancerous lesions, another digital pathology startup is touting the results of a study claiming its deep learning technology can detect melanoma with a high degree of accuracy.
Philadelphia-based Proscia shared the results of a prospective study testing its DermAI software on skin biopsies from two different laboratories. It found that its AI detected melanoma in situ and invasive melanoma with a sensitivity of 93% and a specificity of 91%.
Proscia has not yet published the results of the prospective study, but it hopes to move...